GLPwatch

Impact of Exenatide on Sleep Duration

NCT01416649 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide affects sleep duration and quality in adults with type 2 diabetes.

Status Completed The study has finished.
Type Observational
Participants 8 people
Who can join Ages 18–75 · all sexes
Timeline Started 2011-02 · est. completion 2021-04
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01416649 ↗

Description as written by the study sponsor.

This study investigates the effect of exenatide, a FDA approved medication for the treatment of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be studied before and during treatment with Exenatide. Enrolled individuals will be asked to come to the University of Chicago for 3-4 outpatient visits over the course of 3-4 months.

Treatments tested

Main thing measuredSleep duration and sleep efficiency
SponsorUniversity of Chicago
Conditions studiedType 2 Diabetes
GLP-1 drugs exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01416649 ↗